 AIM ImmunoTech Inc NYSE:AIM said data from a study evaluating the direct effects of its flagship drug candidate Ampligen rintatolimod on human pancreatic ductal adenocarcinoma PDAC cells has been accepted for presentation at the upcoming 15th Annual International Hepato-Pancreato-Biliary Association IHPBA World Congress in New York City. We are encouraged by the data demonstrated by Ampligen and its potential to offer beneficial anti-tumor effects in pancreatic cancer patients, AIM ImmunoTech CEO Thomas Equels said in a statement. 